Edition:
United States

People: Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

67.85USD
9 Dec 2016
Change (% chg)

$0.66 (+0.98%)
Prev Close
$67.19
Open
$67.22
Day's High
$68.16
Day's Low
$67.22
Volume
1,196,102
Avg. Vol
1,292,400
52-wk High
$87.20
52-wk Low
$64.25

Lundberg, Jan 

Dr. Jan M. Lundberg Ph.D., is an Executive Vice President - Science and Technology, President - Lilly Research Laboratories of the Company. Dr. Lundberg has a Ph.D. from Sweden's Karolinska Institute, where he was a professor in the department of pharmacology before moving to industry. Prior to Karolinska, he attended Gustavus Adolphus College in Minnesota and the University of Gothenburg in Sweden. He has been a member of the Swedish Medical Research Council and of the Advisory Board for Drug Approvals at the Swedish Medical Product Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy at Uppsala University. During the last 10 years at AstraZeneca, as head of global discovery research, he was instrumental in delivering 150 drug candidates to the company's pipeline. He had a role in external activities, including in-licensing of projects and technologies, as well as acquisitions of biotech companies. His organization was with both small molecules and biologics. For the past seven years, he has been an executive vice president and member of the senior executive team, reporting to the CEO of AstraZeneca.

Basic Compensation

Total Annual Compensation, USD 2,468,240
Restricted Stock Awards, USD 3,859,000
Long-Term Incentive Plans, USD --
All Other, USD 451,116
Fiscal Year Total, USD 6,778,350

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Lechleiter

16,562,500

Derica Rice

6,935,410

Maria Crowe

--

Jan Lundberg

6,778,350

Melissa Barnes

--

Michael Harrington

4,780,500
As Of  30 Dec 2015